Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment |
| |
| Authors: | Ibrahim Koral Onal Bulent Altun Eda Demir Onal Alper K?rkpantur Serife Gul Oz Cetin Turgan |
| |
| Institution: | 1. Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland;2. Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland;3. Global Drug Discovery, Bayer Healthcare, Berlin, Germany;4. Clinic for Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland;1. Department of Cardiovascular Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China;2. Department of Cardiothoracic Surgery, First Hospital of Qiqihaer, Qiqihaer, China;3. Department of Geriatrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, China;1. First University Department of Cardiology, Hippokration Hospital, University of Athens, Athens, Greece;2. Department of Cardiology, Hippokration Hospital, Athens, Greece;3. Department of Cardiology, Elena Venizelou Hospital, Athens, Greece;1. Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA;2. Departments of Biochemistry and Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USA;3. Department of Biological Sciences, University of Massachusetts Lowell, Lowell, MA 01854, USA |
| |
| Abstract: | BackgroundMatrix metalloproteinases, a family of proteolytic enzymes are thought to be involved in extracellular matrix accumulation during development of hypertensive target organ disease. The present study was designed to compare hypertensive patients with normotensive individuals with respect to serum levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and to search for the effect of antihypertensive treatment on the serum enzyme levels.MethodsThirty-three patients with stage 1 primary hypertension and sixteen age- and sexmatched control subjects were enrolled into the study. Serum MMP-9 and TIMP-1 levels were assessed in the hypertensive group before and after a 3-month-antihypertensive treatment (candesartan 8 mg/day to 17 patients and lisinopril 10 mg/day to 16 patients).ResultsPre-treatment serum MMP-9 levels were higher in the hypertensive group (p = 0.309) while serum TIMP-1 levels were lower (p = 0.296). Serum MMP-9 levels were decreased (p < 0.001) and TIMP-1 levels were increased (p = 0.022) after the antihypertensive treatment.ConclusionsIn hypertensive patients, increased MMP-9 activity could result in increased degradation of elastin relative to collagen and non-elasticity, while decreased TIMP-1 activity could lead to accumulation of poorly cross-linked, immature and unstable fibril degradation products, which result in misdirected deposition of collagen. Our study is important for revealing the role of the MMP enzyme system in the pathogenesis of hypertensive target organ disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
